Grant Award Details

Novel Rejuvenated T Cell Immunotherapy for Lung Cancer
Grant Type: 
Grant Number: 
DISC2-08874
Project Objective: 

  • A cellular immunotherapy approach (candidate) that targets non-small cell lung carcinoma (NSCLC) with EGFR mutations, and colorectal cancer (CRC) with KRAS mutations.   

Investigator: 
Name: 
Institution: 
Type: 
PI
Disease Focus: 
Cancer
Lung Cancer
Solid Tumors
Human Stem Cell Use: 
iPS Cell
Cell Line Generation: 
iPS Cell
Award Value: 
$1,968,456
Status: 
Active

Progress Reports

Reporting Period: 
Year 2

Grant Application Details

Application Title: 
  • Novel Rejuvenated T Cell Immunotherapy for Lung Cancer
Public Abstract: 

Research Objective

Through this project, we would like to evaluate how this T-iPSC-based immunotherapy that we have developed can eliminate lung cancer cells effectively in vivo using xenografted SCID mice.

Impact

This novel T-iPSC-based immunotherapy will provide another effective treatment for lung cancer and possible other malignancies by supplying unlimited number of young and active CTLs.

Major Proposed Activities

  • Peptides synthesis for EGFR mutation hot spots and selection of the peptides with affinity binding assay
  • Patient lung cancer/ blood cell culture and xenograft establishment in SCID mice for establishing tumor model
  • Peptide responsive T cell selection, IPS induction and T cell redifferentiation and expansion (rejCTL) for cell-based immunotherapy
  • transfusion of patient specific rejCTL cells into lung cancer grafted mice to treat tumors
  • Evaluation of the efficacy of rejCTL cell therapy by observing tumor sizes in xenografted mice
  • Statistical analysis and conclusion for this novel cell-based cancer treatment and contact FDA for initiation of a clinical trial
Statement of Benefit to California: 

Lung cancer is known to cause the highest fatality rate. California State and citizens suffer similarly as the US and worldwide do. A fairly common HLA allele, e.g. HLA A0201 presents in up to 50% of California populations. Thus, we can provide an ‘off the shelf’ therapy for most of cancer patients. As a California based institute, we will succeed this research and pioneer this frontier cell- based immunotherapy, and conduct a possible clinical trial through CIRM funding.

  • Share

Publications

PrintPDF version